Changes in isotretinoin prescribing before and after implementation of the System to Manage Accutane Related Teratogenicity™ (SMART™) risk management program

Abstract

SMART may have lead to a decrease in isotretinoin prescriptions. Further research is needed to determine whether the reduced number of isotretinoin prescriptions reflects appropriate use or inhibited use resulting in loss of access to the product's benefits.